Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.0400+0.1500 (+5.19%)
At close: 04:00PM EDT
3.0200 -0.02 (-0.66%)
After hours: 07:54PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.8900
Open2.9800
Bid2.8900 x 900
Ask3.0200 x 1100
Day's Range2.9600 - 3.3500
52 Week Range2.0300 - 18.9600
Volume296,383
Avg. Volume1,269,833
Market Cap99.276M
Beta (5Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)-0.2980
Earnings DateMar 09, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
  • GlobeNewswire

    Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

    SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Florida Medicaid Pharmaceutical & Therapeutics Committee has approved adding GIMOTI, the Company’s novel treatment solution meant to treat symptoms associated with acute and recurrent diabetic gastroparesis, to the Florida M

  • GlobeNewswire

    Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

    SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it received written notice from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the

  • GlobeNewswire

    Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported

    Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide Supports Safety Profile of Only Approved Molecule in US to Treat Symptoms of Acute and Recurrent Diabetic Gastroparesis SOLANA BEACH, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an

Advertisement
Advertisement